Literature DB >> 15592904

Ciprofloxacin treatment failure in a patient with resistant Streptococcus pneumoniae infection following prior ciprofloxacin therapy.

M W R Pletz1, L McGee, O Burkhardt, H Lode, K P Klugman.   

Abstract

Reported here is the case of a patient with underlying chronic obstructive pulmonary disease (COPD) in whom ciprofloxacin treatment of a lower respiratory tract infection failed subsequent to ciprofloxacin treatment of an exacerbation of COPD several weeks earlier. During the second course of ciprofloxacin therapy, the patient's condition continued to deteriorate, and she was admitted to the intensive care unit. Bilateral pneumonia was diagnosed. Streptococcus pneumoniae, serotype 11A, resistant to ciprofloxacin was isolated from the sputum. Sequencing revealed a S79F mutation in parC and there was evidence of an efflux pump. The patient improved rapidly after administration of azithromycin and ampicillin/sulbactam. This report of treatment failure due to ciprofloxacin-resistant Streptococcus pneumoniae shows that fluoroquinolones should be avoided when treating patients who have recently received this class of antibiotics.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15592904     DOI: 10.1007/s10096-004-1254-x

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  10 in total

1.  Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.

Authors:  Ross Davidson; Rodrigo Cavalcanti; James L Brunton; Darrin J Bast; Joyce C S de Azavedo; Pamela Kibsey; Christine Fleming; Donald E Low
Journal:  N Engl J Med       Date:  2002-03-07       Impact factor: 91.245

2.  Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia.

Authors:  Jim Hutchinson
Journal:  N Engl J Med       Date:  2002-07-04       Impact factor: 91.245

3.  Fluoroquinolone resistance in Streptococcus pneumoniae: evidence that gyrA mutations arise at a lower rate and that mutation in gyrA or parC predisposes to further mutation.

Authors:  Stephen H Gillespie; Leroy L Voelker; Jane E Ambler; Chris Traini; Anne Dickens
Journal:  Microb Drug Resist       Date:  2003       Impact factor: 3.431

4.  Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia.

Authors:  Michael B Kays; David W Smith; Matthew E Wack; Gerald A Denys
Journal:  Pharmacotherapy       Date:  2002-03       Impact factor: 4.705

5.  Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia.

Authors:  Kevin B Anderson; James S Tan; Thomas M File; Joseph R DiPersio; Barbara M Willey; Donald E Low
Journal:  Clin Infect Dis       Date:  2003-07-14       Impact factor: 9.079

6.  Primary targets of fluoroquinolones in Streptococcus pneumoniae.

Authors:  H Fukuda; K Hiramatsu
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

7.  Clonal distribution of invasive pneumococcal isolates from children and selected adults in the United States prior to 7-valent conjugate vaccine introduction.

Authors:  Robert E Gertz; M Catherine McEllistrem; David J Boxrud; Zhongya Li; Varja Sakota; Terry A Thompson; Richard R Facklam; John M Besser; Lee H Harrison; Cynthia G Whitney; Bernard Beall
Journal:  J Clin Microbiol       Date:  2003-09       Impact factor: 5.948

8.  Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy.

Authors:  Delphine Croisier; Manuel Etienne; Emilie Bergoin; Pierre-Emmanuel Charles; Catherine Lequeu; Lionel Piroth; Henri Portier; Pascal Chavanet
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

9.  Antimicrobial susceptibility breakpoints and first-step parC mutations in Streptococcus pneumoniae: redefining fluoroquinolone resistance.

Authors:  Sue Lim; Darrin Bast; Allison McGeer; Joyce de Azavedo; Donald E Low
Journal:  Emerg Infect Dis       Date:  2003-07       Impact factor: 6.883

10.  Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults.

Authors:  Lionel A Mandell; John G Bartlett; Scott F Dowell; Thomas M File; Daniel M Musher; Cynthia Whitney
Journal:  Clin Infect Dis       Date:  2003-11-03       Impact factor: 9.079

  10 in total
  5 in total

1.  Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.

Authors:  Daniel E Rozen; Lesley McGee; Bruce R Levin; Keith P Klugman
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

Review 2.  Drug-resistant pneumococcal pneumonia: clinical relevance and approach to management.

Authors:  J D Fuller; A McGeer; D E Low
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-12       Impact factor: 3.267

Review 3.  Bronchiectasis--diagnosis and treatment.

Authors:  Jessica Rademacher; Tobias Welte
Journal:  Dtsch Arztebl Int       Date:  2011-12-02       Impact factor: 5.594

Review 4.  Resistance surveillance studies: a multifaceted problem--the fluoroquinolone example.

Authors:  A Dalhoff
Journal:  Infection       Date:  2012-03-30       Impact factor: 3.553

5.  Global fluoroquinolone resistance epidemiology and implictions for clinical use.

Authors:  Axel Dalhoff
Journal:  Interdiscip Perspect Infect Dis       Date:  2012-10-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.